David W. Dempster

David W. Dempster

Auto-generated profile, based on publicly available information

David W. Dempster

Regional Bone Center Helen Hayes Hospital West Haverstraw NY USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2012 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DDDavid W Dempster
David W Dempster
JCJuliet E Compston
Juliet E Compston
MDMarc K Drezner
Marc K Drezner
FGFrancis H Glorieux
Francis H Glorieux
JKJohn A Kanis
John A Kanis
APA Michael Parfitt
A Michael Parfitt
Click on the article title to read more.

1 March 2012 in Clinical Therapeutics
Verified
Journal Article
Closed access
DDDavid W. Dempster
David W. Dempster
CLCheryl L. Lambing
Cheryl L. Lambing
PKPaul J. Kostenuik
Paul J. Kostenuik
AGAndreas Grauer
Andreas Grauer


16 April 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DDDavid W Dempster
David W Dempster
JBJacques P Brown
Jacques P Brown
AFAstrid Fahrleitner-Pammer
Astrid Fahrleitner-Pammer
DKDavid Kendler
David Kendler
SRSebastien Rizzo
Sebastien Rizzo
GBGeorges Boivin
Georges Boivin
Context: Denosumab is a potent antiresorptive agent that reduces fractures in postmenopausal women with osteoporosis. Objective: Determine effects of up to 10 years of denosumab on bone histology, remodeling, and matrix mineralization characteristics. Design and Setting: International, multicenter, randomized, double-blind trial [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM)] with a long-term open-label extension. Patients: Postmenopausal women with osteoporosis (92 women in FREEDOM, 46 in extension) who provided iliac bone biopsies, including 11 who provided biopsies at multiple time points. Interventions: FREEDOM subjects were randomized 1:1 to subcutaneous denosumab 60 mg or placebo every 6 months for 3 years. Long-term extension subjects continued receiving denosumab, open-label, for 7 additional years. Outcomes: Bone histology, histomorphometry, matrix mineralization. Results: Ten-year denosumab biopsies showed normal histology. Bone histomorphometry indicated normal bone structure and reduced bone remodeling after 10 years of denosumab, similar to levels after 2 and/or 3 and 5 years of denosumab. The degree of mineralization of bone was increased and mineralization heterogeneity was reduced in the denosumab years 2/3 group vs placebo. Changes in these mineralization variables progressed from years 2/3 to year 5 of denosumab, but not thereafter. Conclusions: Denosumab for 2/3, 5, and 10 years was associated with normal histology, low bone remodeling rate, increased matrix mineralization, and lower mineralization heterogeneity compared with placebo. These variables were unchanged from year 5 to year 10. These data, in combination with the maintenance of low fracture rates for up to 10 years as previously reported with denosumab therapy, suggest that strong, prolonged remodeling inhibition does not impair bone strength.

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
JPJanice Pasieka
Janice Pasieka
KWKelly Wentworth
Kelly Wentworth
CYCaitlin T Yeo
Caitlin T Yeo
SCSerge Cremers
Serge Cremers
DDDavid Dempster
David Dempster
DSDolores M. Shoback
Dolores M. Shoback
The approach utilized a systematic review of the medical literature executed with specifically designed criteria that focused on the etiologies and pathogenesis of hypoparathyroidism. Enhanced attention by endocrine surgeons to new knowledge about parathyroid gland viability are reviewed along with the role of intraoperative parathyroid hormone (ioPTH) monitoring during and after neck surgery. Nonsurgical etiologies account for a significant proportion of cases of hypoparathyroidism (~25%), and among them, genetic etiologies are key. Given the pervasive nature of PTH deficiency across multiple organ systems, a detailed review of the skeletal, renal, neuromuscular, and ocular complications is provided. The burden of illness on affected patients and their caregivers contributes to reduced quality of life and social costs for this chronic endocrinopathy. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

12 October 2017 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
DDDavid W Dempster
David W Dempster
HZHua Zhou
Hua Zhou
RRRobert R Recker
Robert R Recker
JBJacques P Brown
Jacques P Brown
CRChristopher P Recknor
Christopher P Recknor
VRValerie A Ruff
Valerie A Ruff